Program
neflamapimod
Also written as “Neflamapimod” and “VX-745”.
Its studies are mostly in Lewy Body Disease · Alzheimer Disease · Ischemic Stroke · Aphasia, Primary Progressive · Huntington Disease, led by EIP Pharma.
Furthest: phase 2, since Apr 3, 20159 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EIP Pharma | 91 open or running | phase 2since Apr 3, 2015 | Apr 3, 2015 | none ahead |
Also a collaborator on its studies: cervomed-inc and voisin-consulting-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2015First studies: 2 phase 2 studies in Alzheimer DiseaseFirst studyNCT02423200, NCT02423122
- Jan 11, 2018Phase 2 study in Alzheimer DiseaseNCT03402659 · 161 enrolled · United States, Czechia, Denmark and more
- Jun 7, 20192 phase 2 studiesNCT04001517, NCT03980938
- Apr 12, 2023Phase 2 study in Lewy Body DiseaseNCT05869669 · 159 enrolled · United States, Netherlands, United Kingdom
- Jan 23, 2025Phase 2 study in Lewy Body DiseaseNCT06815965 · 26 enrolled · France
- May 5, 2025Phase 2 study in Ischemic StrokeNCT06987643 · 45 enrolled · Australia
- Jun 13, 2025Phase 2 study in Brain DiseasesNCT07033481 · 20 enrolled · United States, United Kingdom
TargetBeta
MAPK14 →read by rule
“MAP kinase p38 alpha inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07033481Brain Diseases · United States, United Kingdom | 2 | Active, not recruiting | Sep 2026 | 20 |
| NCT06987643Ischemic Stroke · Australia | 2 | Completed | Sep 23, 2026 | 45 |
| NCT06815965Lewy Body Disease · France | 2 | Completed | Mar 11, 2026 | 26 |
| NCT05869669Lewy Body Disease · United States, Netherlands, United Kingdom | 2 | Completed | May 29, 2025 | 159 |
| NCT04001517Lewy Body Disease · United States, Netherlands | 2 | Completed | Jun 30, 2020 | 91 |
| NCT03980938Huntington Disease · United Kingdom | 2 | Terminated | Oct 15, 2020 | 15 |
| NCT03402659Alzheimer Disease · United States, Czechia, Denmark and more | 2 | Completed | Jun 30, 2019 | 161 |
| NCT02423122Alzheimer Disease · Netherlands | 2 | Completed | Jul 2016 | 16 |
| NCT02423200Alzheimer Disease · United States | 2 | Completed | Sep 2016 | 16 |
How it is read
Names in the registry
- “Neflamapimod”, 4 entries
- “neflamapimod”, 3 entries
- “VX-745”, 2 entries
Conditions, from the studies’ own filings
- Lewy Body Disease, 3 studies
- Alzheimer Disease, 3 studies
- Ischemic Stroke, 1 study
- Aphasia, Primary Progressive, 1 study
- Huntington Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.